Post-marketing surveillance data of thrombomodulin alfa: Sub-analysis in patients with sepsis-induced disseminated intravascular coagulation

Journal of Intensive Care

Volumn 2, Issue 1, 2014, Pages

  Eguchi, Yutaka ^a,k   Gando, Satoshi ^b   Ishikura, Hiroyasu ^c   Saitoh, Daizoh ^d   Mimuro, Jun ^e,k   Takahashi, Hoyu ^f,k   Kitajima, Isao ^g,k   Tsuji, Hajime ^h,k   Matsushita, Tadashi ^i,k   Tsujita, Ryuichi ^j   Nagao, Osamu ^j   Sakata, Yoichi ^e,k  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f Niigata Prefectural Kamo Hospital   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

^h KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

ⁱ NAGOYA UNIVERSITY HOSPITAL   (Japan)

^j ASAHI KASEI PHARMA CORPORATION   (Japan)

^k Japan Soc on Thromb and Hemostasis Post Marketing Surveillance Committee for Thrombomodulin Alfa   (Japan)

more..

Author keywords

Anticoagulant; JAAM criteria; Sepsis; SIRS; SOFA score

Indexed keywords

EID: 84988695174     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/2052-0492-2-30     Document Type: Article

References (24)

1. Levi M: Disseminated intravascular coagulation. Crit Care Med 2007, 35:2191-2195
2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709
3. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM: KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878
4. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430
5. Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T, Maruyama I: Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008, 28:1825-1830
6. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, Kuo CH, Chang BI, Chang CF, Lin CH, Wong CH, Wu HL: Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008, 112:3661-3670
7. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007, 5:31-41
8. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, Hirayama A, Aoki Y, Aoki O: Thrombomodulin a in the treatment of septic patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011, 35:349-354
9. Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, Kuroda T, Sakata Y: Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res 2013, 131:436-443
10. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S: Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group, Shimazaki S: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34:625-631
11. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definition for sepsis and organ failure and guidelines for the use innovative therapies in sepsis. Crit Care Med 1992, 20:864-874
12. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS: Zimmerman JL, for the International Surviving Sepsis Campaign Guidelines Committee, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327
13. Northrop Grumman Corporation. MedDRA and MSSO: Northrop Grumman Corporation website. http://www.meddra.org; April 8, 2011
14. ICH Steering Committee. ICH Harmonised Tripartite Guideline: Clinical safety data management: definitions and standards for expedited reporting. http://www.pmda.go.jp/ich/e/e2a_95_3_20e.pdf; April 8, 2011
15. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Otomo Y, Okamoto K, Kushimoto S, Endo S: Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group, Shimazaki S: Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis. Thromb Res 2009, 123:715-718
16. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL: Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286:1754-1758
17. Mosnier LO, Zolkovic BV, Griffin JH: The cytoprotective protein C pathway. Blood 2007, 109:3161-3172
18. Ito T, Maruyama I: Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011, 1:168-173
19. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T: Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011, 15:R123
20. Kudo D, Shinozawa Y, Yamanouchi S, Endo T, Sato T, Furukawa H, Nomura R, Kushimoto S: Treatment effect of thrombomodulin-a on septic disseminated intravascular coagulation (DIC): a historical cohort study (in Japanese). J Jpn Soc Intensive Care Med 2012, 19:359-366
21. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, Nakamori Y, Inoue Y, Kuwagata Y, Tanaka H, Hamasaki T, Shimazu T: Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013, 39:644-652
22. Khan A, Agarwal R, Aggarwal AN, Gupta D: Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis. Respir Care 2010, 55:901-910
23. Vincent JL, Ramesh MK, Ernest D, Larosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I: A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013, 41:2069-2079
24. Kato T, Sakai T, Kato M, Hagihara M, Hasegawa T, Matsuura K, Nakagawa T: Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J 2013, 11:3